Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Southern Copper Corp (SCCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Southern Copper Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Southern Copper Corp trades at $166.06 (market cap $141.63B). The key difference: Southern Copper Corp is far larger — about 31.5× ACADIA Pharmaceuticals Inc.'s market cap, and Southern Copper Corp pays a 2.36% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | SCCO | |
|---|---|---|
Market Cap | $4.49B | $141.63B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $218.85 |
52-Week Low | $20.06 | $90.54 |
Enterprise Value | $3.69B | $143.68B |
Dividend Yield | — | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Southern Copper (SCCO) trades at $169.75, down 1.31% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 34.13% net income margin and robust earnings beats in recent quarters. Revenue growth accelerated to $13.42B in 2025, and the company maintains a solid cash flow profile with $4.75B from operations. Recent corporate actions include a $1.00 dividend and a minor stock split.
SCCO's outlook is supported by copper demand linked to AI infrastructure, but high valuation ratios (P/E 29.44) and bearish technicals pose risks. Analyst consensus is cautious with a $151.21 price target below the current price. Key risks include commodity price volatility and execution challenges in mining operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
